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INTRODUCTION
T he Triggering Receptor Expressed on Myeloid cells 1 (TREM-1) is a cell-surface receptor of the immunoglobulin superfamily, involved in the innate inflammatory response to bacterial and fungal infections (Bleharski et al., 2003) . Early studies have demonstrated the role of TREM-1 in the development of septic shock (Bouchon et al., 2001; Begum et al., 2004) . It was further demonstrated that the systemic production of TREM-1 is enhanced in infections of the respiratory track, the gut, or the amniotic fluid (Begum et al., 2004; Buckland et al., 2011) . TREM-1 is produced primarily by monocytes (Cavaillon, 2009; Arts et al., 2011) and regulates immune cell functions in a manner that leads to the enhancement of the inflammatory response (Colonna and Facchetti, 2003; Ford and McVicar, 2009 ). The engagement of TREM-1 in in vivo and in vitro models by agonist monoclonal antibodies further stimulates the production of pro-inflammatory cytokines (Bouchon et al., 2001; Bleharski et al., 2003; Radsak et al., 2004; Bostanci et al., 2011) . A synergism exists between the activation of TREM-1 and Toll-like receptors or Nod-like receptors, resulting in amplification of pro-inflammatory cytokines, including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and inhibition of anti-inflammatory cytokines such as IL-10 (Bleharski et al., 2003) . Hence, the role of TREM-1 in innate immunity appears to be the regulation of the magnitude of the inflammatory response to bacterial challenge. Of relevance to periodontal disease is the finding that Porphyromonas gingivalis induces TREM-1 production in monocytes, characterized by a shift from the cell bound to its soluble form, along with the propagation of pro-inflammatory cytokine production (Liang et al., 2009; Bostanci et al., 2011) . This effect can be diminished by the administration of doxycycline in the experimental system (Bostanci and Belibasakis, 2012) .
Since TREM-1 is released during the course of infection in the form of soluble (s)TREM-1, it can serve as a particularly useful marker of systemic inflammation. This has been well-demonstrated in systemic sepsis (Gibot et al., 2004a,b; Su et al., 2012) , arthritis (Murakami et al., 2007; Collins et al., 2009) , pulmonary infections (Ruiz-Gonzalez et al., 2011) , pancreatitis (Yasuda et al., 2008) , and inflammatory bowel disease (Park et al., 2009) . sTREM-1 is a biomarker that can easily be measured in biological fluids (Skogstrand et al., 2005) . The presence of sTREM-1 in serum could be attributed to circulating leukocytes during the course of systemic infection or could account for locally produced sTREM-1 in focal infections, which eventually enters the blood stream (Bleharski et al., 2003) .
Even though the systemic involvement of sTREM-1 has been demonstrated in several infections, little is known about its association with periodontal disease. Thus, the hypothesis of this study was that oral and systemic Elevated Oral and Systemic Levels of Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) in Periodontitis TREM-1 levels are elevated in periodontitis and could constitute a systemic biomarker for the disease. Therefore, the aim of the study was to investigate salivary and serum sTREM-1 levels in individuals without periodontitis and those with chronic or aggressive periodontitis.
MATERIALS & METHODS

Study Population and Clinical Examination
In total, 63 individuals were included in this study, recruited from the Department of Periodontology, School of Dentistry, Ege University, İzmir, Turkey, from November 2011 until March 2012. The use of humans for study satisfied the requirements of the Ege University Institutional Review Board (ethics approval number: 11-12.1/11) and was conducted in accordance with the guidelines of the World Medical Association Declaration of Helsinki. It is confirmed that this cross-sectional study conforms to STROBE guidelines for observational studies. Complete medical and dental histories were taken from all participants. Systemic exclusion criteria were the presence of cardiovascular and respiratory diseases, diabetes mellitus, HIV infection, systemic inflammatory conditions or non-plaqueinduced oral inflammatory conditions, immunosuppressive chemotherapy, and current pregnancy or lactation. None of the patients had taken medication such as antibiotics or antiinflammatory drugs that could affect their periodontal status for at least 6 mos before the study. Patients eligible for the study returned to the clinic for clinical measurement screening 1 wk after being pre-screened. Smoking status was also recorded, and participants smoking > 5 cigarettes per day were registered as smokers. Before being enrolled in the study, participants provided written and informed consent. Patient selection was based on clinical and radiographic criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions (Armitage, 1999) . The clinical measures and patient demographics are described in the Appendix.
Collection and Processing of Saliva and Serum
All clinical samples (saliva and serum) were collected in the morning between 8 a.m. and 11 a.m. Participants were asked to avoid oral hygiene measures (i.e., flossing, brushing, and mouthrinses), eating, and drinking for 2 hrs before collection. For saliva collection, the participants were asked to rinse their mouths with tap water, following which they expectorated whole saliva into sterile 50-mL tubes for 5 min. All saliva samples were placed on ice, supplemented with EDTA-free Protease Inhibitor Cocktail (Roche Applied Science, Geneva, Switzerland) prior to centrifugation at 10,000 x g for 15 min at 4°C (Navazesh, 1993) . Finally, the resulting supernatants were then immediately aliquoted and frozen at −80°C. For serum samples, 5-mL quantities of venous blood were taken into vacutainers (BD Diagnostics, Franklin Lakes, NJ, USA) by a standard venipuncture method. Once collected, the samples were left at room temperature to allow for blood clotting and then centrifuged to remove the fibrin clot and cellular elements for 15 min at 1,500 x g at 4°C. All serum samples were placed on ice, supplemented with EDTA-free Protease Inhibitor Cocktail (Roche Applied Science). Finally, they were immediately aliquoted and frozen at −80°C. Further analysis of the saliva and serum samples by ELISA is described in the Appendix.
Statistical Analysis
Statistical analysis was performed by non-parametric methods. Comparisons among all groups were performed by the Kruskal-Wallis test. When significant differences were observed (p < 0.008), then two-group comparisons were assessed with Mann-Whitney U tests with Bonferroni correction, and p < 0.05 was considered to be statistically significant. Correlations between sTREM-1 levels and clinical parameters were analyzed by Spearman's rank test, and p < 0.01 values were considered as significant. Statistical analyses were conducted with the statistical software SPSS v. 19.0 (IBM, Somers, NY, USA).
RESULTS
Clinical Findings
The full-mouth clinical findings are provided in Table 1 . Mean probing pocket depth, clinical attachment loss, plaque index, and bleeding on probing scores were significantly higher in the chronic and generalized aggressive periodontitis groups than in the control group (p < 0.0001). No significant differences were detected in these clinical measurements between the two periodontitis groups.
Analysis of sTREM-1 Levels in Saliva
Saliva samples were collected from 59 individuals (control, n = 18; chronic periodontitis, n = 20; generalized aggressive periodontitis, n = 21). The concentrations of sTREM-1 in these samples were further analyzed by ELISA. sTREM-1 was detected in all samples. The mean concentrations were 384.60 ± 115.81 pg/mL in the control group, 1,272.38 ± 138.91 pg/mL in the chronic periodontitis group (3.3-fold higher than in the control group), and 2,179.95 ± 306.14 pg/mL in the generalized aggressive periodontitis group (5.6-fold higher than in the control group) (Fig.  1A) . The differences between the control group and groups with either form of periodontitis were statistically significant, whereas the difference between the two periodontitis groups was not.
Since salivary flow rate may reflect differences in composition, the salivary sTREM-1 concentrations were also corrected for total protein content. It was found that total protein concentrations were 1.73 ± 0.28 mg/mL, 2.03 ± 0.31 mg/mL, and 2.49 ± 0.43 mg/mL in the control, chronic periodontitis, and generalized aggressive periodontitis groups, respectively. Accordingly, the calibrated-to-protein salivary levels of sTREM-1 were 212.18 ± 32.23 pg/mg, 914.45 ± 170.99 pg/mg, and 1,127.16 ± 133.63 pg/ mg in the control group, chronic periodontitis group (4.3-fold higher than in the control group), and generalized aggressive periodontitis group (5.3-fold higher than in the control group), respectively (Fig. 1B) . The differences between the control group and the chronic or generalized aggressive periodontitis group were statistically significant (p < 0.0001), whereas the difference between the two periodontitis groups was not. Salivary sTREM-1 levels (both pg/mL and pg/mg protein) correlated positively (p < 0.01) with all full-mouth clinical parameters measured (Table 2 ). There were no significant differences in salivary sTREM-1 concentrations or calibrated-to-protein amounts between smokers and non-smokers. There was also a positive correlation between IL-1β and sTREM-1 concentrations and calibrated-to-protein amounts in saliva (r = 0.587 and r = 0.565, respectively, p < 0.05). The analysis of IL-1β levels in saliva is provided in the Appendix.
Analysis of sTREM-1 Levels in Serum
Serum samples were available from 62 participants (control, n = 20; chronic periodontitis, n = 22; generalized aggressive periodontitis, n = 20) and analyzed by ELISA for the concentrations of sTREM-1, which was detected in all samples. These concentrations were 306.49 ± 18.65 pg/mL in the control group, 536.89 ± 43.98 pg/mL in the chronic periodontitis group, and 621.7 ± 54.35 pg/mL in the generalized aggressive periodontitis group (Fig. 2) . These differences represent a 1.75-fold increase in chronic periodontitis and a 2-fold increase in generalized aggressive periodontitis, compared with the control group. The differences between the control group and the groups with either form of periodontitis were statistically significant (p < 0.0001), whereas there were no differences between the groups with the 2 forms of periodontitis. Serum TREM-1 levels also positively correlated (p < 0.01) with all full-mouth clinical parameters (Table 2) . There was no significant difference (p > 0.05) in sTREM-1 serum concentrations between smokers and non-smokers. The difference between the chronic periodontitis and generalized aggressive periodontitis groups was not significant. 
Correlation Analysis between Saliva and Serum sTREM-1 Levels
The potential correlation between sTREM-1 levels in saliva and serum was also investigated in the 58 participants with the available matched samples, and a positive correlation between sTREM-1 concentrations in serum and saliva was revealed (r = 0.48, p < 0.0001).
DISCUSSION
The present study is the first to investigate the oral and systemic levels of sTREM-1 in periodontal disease by analyzing its concentrations in serum and saliva, respectively. The results demonstrated that the levels of sTREM-1 in saliva and serum are significantly higher in patients with chronic and generalized aggressive periodontitis, compared with individuals without periodontitis. There were no differences between these 2 forms of periodontitis. Moreover, a positive correlation was revealed between clinical periodontal measurements and levels of sTREM-1. This indicates that the occurrence and severity of periodontitis match elevated oral and systemic sTREM-1 levels. Given the involvement of this molecule in the propagation of the local and systemic inflammatory response, these findings could provide a further link between periodontitis and systemic inflammation (Hasturk et al., 2012) . Numerous systemic biomarkers have been studied for their relevance to periodontal health and disease. For instance, C-reactive protein (CRP), a systemic marker of the acute-phase inflammatory response, has been measured in saliva and serum, and can differentiate periodontal health from periodontal disease, since its levels are elevated in disease (D'Aiuto et al., 2004; Christodoulides et al., 2005) . When compared with CRP or procalcitonin, a marker that can differentiate between infectious and non-infectious inflammation, serum and urine sTREM-1 shows higher sensitivity and specificity for detecting systemic inflammation in early bacterial sepsis (Su et al., 2012) . In this respect, sTREM-1 could well serve as a biomarker representative of the inflammatory state of infected periodontal tissues. The nature of periodontitis as a focal infection and its well-documented association with systemic inflammation provide a good rationale for the study of sTREM-1 systemic responses in this disease. Indeed, analysis of the present data demonstrates a significant increase of salivary and serum sTREM-1 in periodontitis compared with non-periodontitis, as well as a positive correlation with disease severity. Moreover, the data provides evidence of a positive correlation between sTREM-1 and IL-1β levels in saliva. This association is in line with in vitro findings that TREM-1 activation enhances IL-1β production (Bostanci et al., 2011) , although the present approach cannot directly reveal a cause-effect relationship between the 2 molecules in saliva. Saliva in particular is a favorable biological analyte for monitoring oral and systemic disease biomarkers because of its non-invasive collection and natural presence in the totality of the oral cavity (Giannobile et al., 2009; Ramseier et al., 2009; Zhang et al., 2009) . Hence, the three-to six-fold increase of sTREM-1 salivary levels in periodontitis can denote the magnitude of pathological regulation, opening the possibility for the use of sTREM-1 as a quantitative biomarker for undiagnosed periodontal disease. At this point, one should also take into consideration that proteinases produced by oral bacteria, particularly those associated with periodontitis, could well degrade sTREM-1 released in saliva. This would mean that the original production of sTREM-1 may be greater than that eventually detected in the salivary environment.
It is likely that inflammatory biomarkers of oral disease would be considerably diluted in serum compared with saliva. This is also reflected in the present study, whereby sTREM-1 concentrations in periodontitis were, by two-fold, higher in saliva than in serum. Since periodontal disease can be a mediator of systemic inflammation and a modifier of the effect of the association with systemic disease, such as diabetes mellitus (Lalla and Papapanou, 2011) , sTREM-1 could provide a risk indicator for systemic inflammation. In the present study, the periodontitis patients were otherwise systemically healthy, with no other indication of an inflammatory or infectious process, and demonstrated almost two-fold higher sTREM-1 serum levels, compared with participants without periodontitis. Hence, one could postulate that the occurrence of periodontitis alone increases by two-fold the circulating levels of sTREM-1 and, consequently, any biological effect that this factor may have on the systemic level. Whether the increased presence of sTREM-1 in the serum of periodontitis patients results from bacteremic challenge of circulating leukocytes by periodontal pathogens, or represents a "leakage" of locally produced sTREM-1 into the circulation, remains unclear. Finally, it is worth noting that, since salivary and serum sTREM-1 does not appear to be affected by smoking, unlike other inflammatory markers (i.e., CRP and several cytokines), it may prove to be a useful biomarker.
Collectively, the present study shows an increase in the oral and systemic levels of sTREM-1 in periodontitis. The 2 main limitations of the study were its cross-sectional nature, which can only confer an association between sTREM-1 and periodontitis but cannot reveal a mechanistic insight or a predictive value for the disease, and its relatively small sample size. Whether sTREM-1 release constitutes a mechanism that contributes to the progression of the disease, or a protective inflammatory reaction to emerging bacterial infection, remains to be elucidated. Whichever the case, the increased presence of this molecule may stand as a biomarker of underlying periodontal disease. This can have diagnostic implications in the detection of untreated periodontitis, but could also denote an increase in the systemic inflammatory burden in the presence of the disease. In either case, the physiological and/or pathological roles of sTREM-1 in periodontal inflammation need to be further investigated to justify its potential value as an indicative or predictive oral biomarker of the disease, or as an indicator of the association between periodontal disease and systemic inflammation.
